These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2295273)

  • 1. The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans.
    McLeod RS; Cohen Z; Vari BJ; Blair JE; Greenberg GR
    Dis Colon Rectum; 1990 Jan; 33(1):21-5. PubMed ID: 2295273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
    Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
    Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery and fate of oral mesalamine microgranules within the human small intestine.
    Layer PH; Goebell H; Keller J; Dignass A; Klotz U
    Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.
    Riley SA; Tavares IA; Bennett A; Mani V
    Br J Clin Pharmacol; 1988 Aug; 26(2):173-7. PubMed ID: 3207553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.
    Sandberg-Gertzén H; Ryde M; Järnerot G
    Scand J Gastroenterol; 1983 Jan; 18(1):107-11. PubMed ID: 6675167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
    Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
    Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol Suppl; 1988; 148():54-9. PubMed ID: 2906478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].
    Keller J; Goebell H; Klotz U; Layer P
    Med Klin (Munich); 1998 May; 93(5):294-9. PubMed ID: 9630813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
    Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
    J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations.
    Christensen LA; Rasmussen SN; Hansen SH
    Acta Obstet Gynecol Scand; 1994 May; 73(5):399-402. PubMed ID: 8009971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1989 Aug; 3(4):333-42. PubMed ID: 2518847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man.
    Yu DK; Morrill B; Eichmeier LS; Lanman RC; Lanman MB; Giesing DH; Weir SJ
    Eur J Clin Pharmacol; 1995; 48(3-4):273-7. PubMed ID: 7589054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.
    Grisham MB; Granger DN
    Dig Dis Sci; 1989 Apr; 34(4):573-8. PubMed ID: 2702889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.